<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Project 1 – Histone Deacetylase Inhibitors</title>
  <link rel="stylesheet" href="../style.css" />
</head>
<body>
  <header>
    <img src="../images/UB_logo.png" alt="University at Buffalo Logo" class="header-logo" />
    <h1>Roberto Pili Lab at the University at Buffalo</h1>
    <nav>
      <ul>
        <li><a href="../index.html">Overview</a></li>
        <li><a href="../team.html">Team</a></li>
        <li><a href="../projects.html" class="active">Research Projects</a></li>
        <li><a href="../contact.html">Contact</a></li>
      </ul>
    </nav>
  </header>

  <main>
    <section>
      <h2>Developing Histone Deacetylase Inhibitors in Genitourinary Cancers</h2>
      <p>
        Our group has been working on the evaluation of HDAC inhibitors as anticancer drugs using pre-clinical models and clinical trials. We have identified several molecular targets of HDAC inhibitors and evaluated their efficacy in preclinical model and clinical trials in prostate and renal cell carcinoma models. In particular, we have reported that pan HDAC inhibitors have an antiangiogenic effect via by inducing degradation of hypoxia inducible factors. Our group has been also among the first to identify the immunomodulatory activities of HDAC inhibitors.
      </p>
      <h3>Key Publications</h3>
      <ul>
        <li>
          Qian DZ, Wang X, Kachhap SK, et al. 
          <i>Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma</i> 
          Cancer Res. 2004;64(18):6626-34. 
          <a href="https://aacrjournals.org/clincancerres/article/23/17/5187/123088/Entinostat-Neutralizes-Myeloid-Derived-Suppressor" target="_blank">PMID: 15374977</a>
        </li>
        <li>
          Qian DZ, Kachhap SK, Collis SJ, et al. 
          <i>Class II histone deacetylases are associated with...</i> 
          Cancer Res. 2006;66(17):8814-21. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/16951198/" target="_blank">PMID: 16951198</a>
        </li>
        <li>
          Pili R, Quinn DI, Hammers HJ, et al. 
          <i>Immunomodulation by Entinostat in Renal Cell Carcinoma Patients...</i> 
          Clin Cancer Res. 2017;23(23):7199-7208. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/28939740/" target="_blank">PMID: 28939740</a>
        </li>
        <li>
          Orillion A, Hashimoto A, Damayanti N, et al. 
          <i>Entinostat Neutralizes Myeloid-Derived Suppressor Cells...</i> 
          Clin Cancer Res. 2017;23(17):5187-5201. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/28698201/" target="_blank">PMID: 28698201</a>
        </li>
      </ul>
    </section>
  </main>

  <footer>
    <p>© 2025 Roberto Pili Lab | University at Buffalo</p>
  </footer>
</body>
</html>